Cencora (COR) Expected to Announce Quarterly Earnings on Wednesday

Cencora (NYSE:COR) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, May 6th. Analysts expect Cencora to post earnings of $4.81 per share and revenue of $81.0878 billion for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:30 AM ET.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm had revenue of $85.93 billion for the quarter, compared to analyst estimates of $86.12 billion. During the same period in the previous year, the company posted $3.73 earnings per share. The company’s quarterly revenue was up 5.5% compared to the same quarter last year. On average, analysts expect Cencora to post $18 EPS for the current fiscal year and $20 EPS for the next fiscal year.

Cencora Trading Down 0.2%

Shares of COR opened at $303.43 on Tuesday. Cencora has a 12-month low of $271.00 and a 12-month high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The firm has a market capitalization of $59.03 billion, a price-to-earnings ratio of 36.47, a P/E/G ratio of 1.42 and a beta of 0.64. The stock’s 50-day moving average price is $333.36 and its 200 day moving average price is $343.31.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date was Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Institutional Investors Weigh In On Cencora

Several large investors have recently modified their holdings of the stock. State Street Corp grew its stake in shares of Cencora by 1.3% in the 4th quarter. State Street Corp now owns 9,305,507 shares of the company’s stock valued at $3,142,935,000 after purchasing an additional 115,191 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Cencora by 80.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,661,769 shares of the company’s stock valued at $1,574,513,000 after purchasing an additional 2,085,473 shares during the period. Wellington Management Group LLP grew its stake in shares of Cencora by 14.2% in the 4th quarter. Wellington Management Group LLP now owns 4,535,992 shares of the company’s stock valued at $1,532,031,000 after purchasing an additional 564,871 shares during the period. Boston Partners grew its stake in shares of Cencora by 2.0% in the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after purchasing an additional 89,506 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Cencora by 5.9% in the 3rd quarter. Northern Trust Corp now owns 2,272,464 shares of the company’s stock valued at $710,213,000 after purchasing an additional 126,929 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on COR. Bank of America lowered their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. JPMorgan Chase & Co. boosted their price target on Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Morgan Stanley set a $380.00 price target on Cencora in a research note on Tuesday, March 17th. Finally, Evercore set a $360.00 price target on Cencora in a research note on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $398.17.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.